{"schema":"hottub-news/story/v1","story":"st_jeobxg3ur3uhji4ptwla","title":"Vom Impfstoff-Superstar zum Ärgernis: Die schwierige Suche nach der Zukunft von Biontech","title_en":"From vaccine superstar to annoyance: The difficult search for the future of Biontech","outlets":1,"brief":null,"page":"https://hottub.news/stories/vom-impfstoff-superstar-zum-argernis-die-schwierige-suche-nach-der-jeobxg3ur3","count":1,"items":[{"id":"n_jeobxg3ur3uhji4ptwla","seq":710643,"kind":"article","title":"Vom Impfstoff-Superstar zum Ärgernis: Die schwierige Suche nach der Zukunft von Biontech","title_en":"From vaccine superstar to annoyance: The difficult search for the future of Biontech","url":"https://www.nzz.ch/wirtschaft/vom-impfstoff-superstar-zum-aergernis-die-schwierige-suche-nach-der-zukunft-von-biontech-ld.10025914","summary":"Das Mainzer Unternehmen schliesst drei Standorte in Deutschland, für die es keinen Käufer gefunden hat. Es konzentriert sich nun voll auf Medikamente gegen Krebs. Der neue Weg ist voller Hindernisse.","published":"2026-09-29T14:57:22Z","seen":"2026-09-29T15:47:41Z","lang":"de","country":"CH","source":{"id":"kite-nzz-ch-607e0a","name":"nzz.ch","domain":"nzz.ch","outlet":{"wikidata":"Q658945","name":"Neue Zürcher Zeitung","type":"newspaper","country":"CH","designations":["daily newspaper"]}},"via":"kite-nzz-ch-607e0a","entities":[{"id":"Q30256699","name":"BioNTech","type":"org"}],"image":"https://img-msp-prod.nzz.ch/2026/09/29/5685698e-bc0d-4fe8-b0c4-7571055f087e.jpg?auto=webp&crop=3786,3786,x1030,y0&fit=bounds&height=200&quality=75&width=200","story":"st_jeobxg3ur3uhji4ptwla","category":"economy-business","category_p":0.25999999046325684,"category2":"science-technology","sentiment":"neutral","tone":-0.17000000178813934,"political":0.05999999865889549}]}